Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar Carcinoma
Stefanie S. Schalm(Blueprint Medicines (United States)), Klaus P. Hoeflich(Translational Research in Oncology)
Cited by 5
Related Papers
Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents
|Breast Cancer Research|2015|74
Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition
|Proceedings of the National Academy of Sciences|2013|56
Regulation of ERK3/MAPK6 expression by BRAF
|International Journal of Oncology|2006|32